Pricing Log in Create free account
Saturday 17 October 2026 Export COR’s income statement to Excel — free account

Cencora, Inc.

COR Healthcare Medical Distribution

Cencora, Inc.’s revenue for fiscal 2025 (year ended September 2025) was $321.3 billion, up 9.31% from fiscal 2024. In the quarter to June 2026, revenue grew 5.07%, EPS grew 11.3%, free cash flow grew 3,385.3% and total debt rose 42.3%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for three consecutive years, revenue growth for ten; insiders bought in the last twelve months.

340.66 0.75 −0.22%
Market cap
$65.2B
P/E
25.2×
Fwd P/E
14.5×
Dividend yield
0.70%
F-score
6/9
Altman Z
4.83
Beneish M
−2.54
Dividend safety
74/100
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Cencora, Inc. 10-K filed Nov 25, 2025

Fiscal year 2025 · Period ended Sep 30, 2025 · Filed · accepted 2:23 PM ET · Document on sec.gov · Filing index

What changed

Item 1, Business Item 1A, Risk Factors Item 7, Management’s Discussion and Analysis

Item 1, Business, against the 10-K filed Nov 26, 2024: 2 added · 13 removed · 41 modified; 3 with only figures updated

  1. Modified · Industry Overview

    Pharmaceutical sales in the United States, as recently estimated by IQVIA, an independent third-party provider of information to the pharmaceutical and healthcare industry, are expected to grow at a compound annual growth rate of approximately 8.28.4% from 20232024 through 20282029, and the growth rate is dependent, in part, on pharmaceutical manufacturer price increases. In addition to general economic conditions, factors that impact the growth of the pharmaceutical industry in the United StatesU.S. and other industry trends include:

55 more changes in this Item, word by word, in Powerpack.

Powerpack